|
 |
| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 12
| Issue : 4 | Page : 147-155 |
|
|
Effect of oral minoxidil for alopecia: Systematic review
Israel Junior Borges do Nascimento1, Matthew Harries2, Vanessa Barreto Rocha3, Jacqueline Y Thompson4, Chun Hoong Wong5, Hamed Kord Varkaneh6, Nathália Sernizon Guimarães7, Alair Junior Rocha Arantes8, Milena Soriano Marcolino8
1 Department of Internal Medicine, University Hospital and School of Medicine, Federal University of Minas Gerais, Brazil; Department of Internal Medicine, School of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2 The Dermatology Centre, University of Manchester, Salford Royal NHS Foundation Trust, Salford; Centre for Dermatology Research, MAHSC and NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, UK
3 Department of Dermatology, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
4 Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, UK
5 Department of Pharmacy, Serdang Hospital, Kajang, Selangor, Malaysia
6 Student Research Commitee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Department of Nutrition, Federal University of Ouro Preto, Ouro Preto, Minas Gerais, Brazil
8 Department of Internal Medicine, University Hospital and School of Medicine, Federal University of Minas Gerais, Brazil
| Date of Submission | 13-Feb-2020 |
| Date of Decision | 14-Apr-2020 |
| Date of Acceptance | 17-Jul-2020 |
| Date of Web Publication | 19-Sep-2020 |
Correspondence Address:
Israel Junior Borges do Nascimento
Medical Research Specialist, Alfredo Balena, 110-1 Andar - Ala Sul, Sala 107, Belo Horizonte 30310-100, Minas Gerais
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_19_20
 Abstract | | |
Patients with major presentations of alopecia experience physically harmful effects and psychological comorbidities, such as depression and anxiety. Oral minoxidil (OM) has been suggested by dermatologists as a potential remedy; however, its effectiveness remains unclear. This systematic review aims to collate published studies and to analyze the effect of OM among patients diagnosed with any type of alopecia. For this systematic review, Medline/PubMed, Cochrane Central, EMBASE, Web of Sciences, and Latin American and Caribbean Health Sciences Information System were searched for relevant studies from inception to September 21, 2019. Of 1960 studies retrieved in several electronic databases and three additional records identified though reference list from potentially eligible studies, nine studies (one randomized controlled trial and eight nonrandomized controlled trials) met the requirements and were used in our analysis. Although we found positive effects in favor of OM, this should be interpreted cautiously due to very low quality of the evidence of outcomes in the selected studies. Definitive conclusions are not possible without high-quality trials. This review has highlighted the absence of high-quality randomized controlled trials evaluating OM in the treatment of various types of alopecia. Given the mild adverse events of OM, future studies should also analyze doses and duration to maximize efficacy and decrease side effects.
Keywords: Alopecia, evidence-based medicine, minoxidil, systematic review
How to cite this article:
do Nascimento IJ, Harries M, Rocha VB, Thompson JY, Wong CH, Varkaneh HK, Guimarães NS, Rocha Arantes AJ, Marcolino MS. Effect of oral minoxidil for alopecia: Systematic review. Int J Trichol 2020;12:147-55 |
How to cite this URL:
do Nascimento IJ, Harries M, Rocha VB, Thompson JY, Wong CH, Varkaneh HK, Guimarães NS, Rocha Arantes AJ, Marcolino MS. Effect of oral minoxidil for alopecia: Systematic review. Int J Trichol [serial online] 2020 [cited 2023 May 30];12:147-55. Available from: https://www.ijtrichology.com/text.asp?2020/12/4/147/295406 |
| Introduction | |  |
Hair plays an important role in sensory function, provides thermal and physical insulation, and confers sociocultural characteristics in humans.[1],[2] Hair production comprises a cycle of growth, shedding, and replacement, with around 50–100 hair lost per day as part of the normal physiological balance. However, unwanted hair loss (termed alopecia) is a clinical condition that develops when degenerative processes outpace hair regeneration.[3],[4],[5] There is a wide spectrum of types and etiologies of alopecia, including androgenetic alopecia (AGA), alopecia areata, scarring alopecia, and telogen effluvium types.[2] Therefore, a proper diagnosis is essential to determine the most appropriate treatment strategy for that individual. A detailed history is vital and should include interrogation of the presenting complaint, medical and family history, diet, and previous treatments. After this, a careful physical examination (including visual inspection and trichoscopy) should be performed.[6],[7] After the diagnosis has been secured, various medications may be appropriate to reestablish the gross hair density and well-being.
The only Food and Drug Administration-approved pharmacological interventions for alopecia are the 5-alpha-reductase type 2 inhibitor finasteride (Propecia®) 1 mg (quantum dot; male-pattern hair loss [MPHL] only) and topical minoxidil (2%–5%) (twice a day; MPHL and female-pattern hair loss only).[8],[9],[10],[11] Minoxidil (empirical formula C9H15N5O) is converted by sulfotransferase into minoxidil sulfate, the active ingredient that promotes hair growth by prolonging anagen and shortening the telogen/kenogen phase, thereby stimulating new hair (NH) production as the next anagen phase begins.[12] Minoxidil was first developed as a topically applied substance for male baldness in 1960 after the Upjohn Company observed increased hair growth as a side effect of oral minoxidil (OM) used to control blood pressure.[13] Since then, clinical trials have demonstrated topical minoxidil as an effective treatment for AGA. Unfortunately, response rates for topical minoxidil are variable (in part related to variations in sulfotransferase levels between individuals), and the regular topical applications to the scalp can be messy and poorly tolerated due to scalp irritation or hair breakage. For these reasons, OM has been suggested as an alternative treatment for alopecia, potentially limiting localized scalp side effects and allowing a higher drug concentration to maximizing treatment response and compliance.[14],[15],[16]
Although topical pharmaceutical formulation of minoxidil has been recognized throughout systematic reviews and meta-analysis to regrow hair in patients affected by different types of alopecia, data on the association between OM and hair growth remain inconsistent and unclear.[17],[18],[19] In this study, we aimed to systematically examine the evidence of an association of OM with hair growth.
| Methodology | | |
The protocol for this systematic review was registered in the PROSPERO database (CRD42019155760), and the completed review conforms to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P).[20]
Search strategy
In order to identify randomized clinical trial assessing the effects of OM in the hair follicle growth, we searched five independent databases to perform the sensitive literature search (publication up to August 2019): 1. PubMed/MEDLINE, 2. Cochrane Central, 3. EMBASE, 4. Latin American and Caribbean Health Science Information, and 5. Web of Science. In addition, we searched for ongoing registered clinical trials at the National Institute of Health United States National Library of Medicine. There was no language, date, document type, or publication status limitations for inclusion of records into the register. We used Medical Subject Headings (MeSH) and non-MeSH terms in order to obtain target articles. Furthermore, a manual search of references of reports of included studies was conducted to further relevant studies.
Eligibility criteria
Inclusion criteria were as follows: (1) randomized controlled trials with crossover/parallel study designs, or nonrandomized controlled studies; (2) studies that were carried out on individuals diagnosed with any type of alopecia of any age; (3) studies that reported sufficient baseline and follow-up data of trials of hair growth/density (e.g., trichoscopic analysis, photographic documentation, biopsy analysis, validated severity scores, or quantitative hair count analysis - such as total hair density/cm2 [THD/cm2], density of terminal hair/cm2 [DTH/cm2], NH/cm2, and new terminal hair/cm2 [NTH/cm2]); also, data on patients' satisfaction, well-being, and adverse effects were included; and (4) studies conducted in a combined therapy (different drugs used at the same time, including OM).
Exclusion criteria were as follows: (1) studies that were carried out on patients with no definite diagnosis of alopecia by a physician; (2) studies that did not provide sufficient information for outcomes in OM or control groups; and (3) case reports with <10 patients in total.
Data extraction
We uploaded electronic search results from the five defined databases to the Rayyan Qatar Computing Research Institute and summarized results using the PRISMA flow diagram [Figure 1].[21] Two authors independently screened the titles and abstracts of records identified without being blinded to authors, institutions, and journal name and assessed each study using the review eligibly criteria. In a case of disagreement between authors, a third expert resolved the conflict. If there was an absence in data reporting, the corresponding author was contacted via E-mail to obtain the required data. If there were missing data within potentially eligible studies, the corresponding author was contacted via E-mail to obtain the required data. The research group developed and piloted a data extraction sheet [Supplemental Material 1] to characterize studies and summarize outcomes. These extraction sheets included information such as first author's name, year of publication, age and gender of individuals, trial duration, study location, type and dosage of OM administration, study design, health status of participants, number of participants in each group, mean and standard deviation (SD) of outcome measures at baseline and posttrial, and/or changes in outcome measures from baseline to the end of the study. If a study reported multiple data points at various points in time, only the most recent data were included. | Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of records investigating effect of oral minoxidil in alopecia
Click here to view |
Quality assessment
Two independent research authors independently assessed the risk of bias of selected studies with input from content experts according to the Cochrane Collaboration's tool was used for assessing risk of bias.[22] Possible sources of bias in randomized trials include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. The most common key sources of biases in dermatology are the nonrandomization of participants in trial, as well as no mutual blinding therapies. In addition, clinical research sponsored by the pharmaceutical industry is progressively reflecting measured outcomes. Three scores of yes, no, and unclear could be given to each aforementioned item, which resulted in classification of high risk, low risk, and unknown risk, respectively. For the randomized controlled trial, we used the software RevMan 5 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) to plot assessments.[23] For nonrandomized controlled studies, we used the updated Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I).[24]
Data synthesis and statistical analysis
In our protocol, we planned to use mean change and SD of the outcome measures to estimate the mean difference between the intervention group and the control group at follow-up. In addition, we also intended to evaluate possible heterogeneity among selected studies using I2, and if substantial heterogeneity (I2 >50%) existed, we explored precise reasons for this. However, due to limited number of studies, we considered the studies clinically heterogeneous and did perform any meta-analysis evaluation. All statistical analyses were performed using Stata software (Stata Corporation, College Station, Texas, United States of America)[25] and are referred as relative frequency and percentage. The adverse effects outcomes were qualitatively showed.
| Results | | |
We identified 1960 studies through five selected database searches with duplicates: 656 references from MEDLINE, 400 from EMBASE, 1 from CENTRAL, 77 from Web of Sciences, and 826 from LILACS. After excluding 788 duplicates, we screened 1175 titles and abstracts. We retrieved full-text articles for the remaining 96 records, of which 87 were excluded due to study design (review articles). We found nine studies eligible that were eligible for inclusion in this review [Table 1]. Throughout reference list checking, we found three additional references. See [Figure 1] for PRISMA diagram, in which presents the overall review pathway as well as the main characteristics of excluded studies.[35]
Included studies
This systematic review includes one randomized controlled trial and eight nonrandomized controlled studies and yielded a pooled sample size of 19,270 patients. Regarding geographic representation of the studies included, we identified studies originating from the Americas,[26],[27],[30],[34] Europe,[28] Oceania,[31],[32] and Asia.[29],[33] No study from Africa was included, and only two studies were in nondeveloped countries. The details of included studies are listed in [Table 1]. Years of publication ranged from 1980 to 2019, and most studies were published in English. OM was mostly given as tablets. The medication was extemporaneously compounded (doses ranged from 0.25 mg to 2.5 mg) in only one study. There was variation in the total oral dose and dose regimens for OM, ranging from 0.25 mg/day to 10.0 mg/day.
Excluded studies
We excluded 87 studies. Eight studies were strictly designed as biological experiments and eleven studies were literature reviews. Other excluded studies did not quantitatively assess the effects of OM. Some excluded articles were published in Portuguese, French, and Spanish but were translated before the final decision to exclude was made.
Incidence of side effects
All included records mentioned side effects associated with OM therapy, as shown in [Table 2]. The most relevant ones were hypertrichosis, postural hypotension, and lower-limb edema. However, the authors described the side effect as “mild” and mostly diluted with continued treatment. | Table 2: Detailed adverse effects in the posttreatment assessment related to oral minoxidil
Click here to view |
Quality assessment
The risk of bias for each study is depicted in [Figure 2]. One randomized controlled trial was included and judged to have a high risk for bias due to lack of blinding of participants and personnel (open study design) and other biases, such as conflict of interest – one of the study authors was affiliated to a pharmaceutical company. Seven quasi-experimental studies were included and judged as having a high risk of bias due to missing data or inadequate measurement of outcomes. Most studies also had selection bias and other biases due to confounding factors (e.g., use of concomitant active drugs for alopecia). Overall, all included studies were associated with a high risk of bias. | Figure 2: Risk of bias summary: Review authors' judgments about each risk of bias item for the included study
Click here to view |
| Discussion | | |
To our knowledge, this is the first systematic review to assess the effectiveness of OM in the treatment of different types of alopecia in human populations. We assessed nine studies (one randomized controlled trial and eight nonrandomized studies), involving a total of 19,270 patients. This high number of patients is fundamentally driven by one specific study (Tanaka et al.), which assessed 18,918 patients. Despite identifying many quasi-experimental studies during the search process and analysis, we could not carry out a meta-analysis as all selected articles had very different measurements of outcomes and methodologies. Overall, most of the outcomes presented in the selected studies were based on few data points, which were of poor quality in the majority of cases. Additionally, the ratings related to the quality of evidence among the included studies were considered as very low for the most relevant outcomes (including hair regrowth).
Interestingly, the positive effect of OM in hair regrowth in patients with various types of alopecia was suggested in all nine selected studies. However, the quality of evidence is extremely compromised due to risk of bias of included studies, heterogeneity, and the involvement or sponsorship of the pharmaceutical industry. This review highlights the need for accepted validated outcome measures in trichology trials to allow consistent interpretation of results across studies. Participants in the identified trials also experienced a range of adverse effects, such as hypertrichosis, hypotensive symptoms, and lower-limb edema, although these were generally mild in severity. We believe that our literature review and data synthesis will provide physicians and researchers with new insight to help decision-making for patients with hair loss.
Minoxidil was initially introduced as an oral antihypertensive agent in the late twentieth century because of its properties to treat ulcer and decrease blood pressure.[36],[37] However, after researchers had found its off-labels effect in hair regrowth, in the 1980s, the Federal Drug Administration approved it as a topical solution for baldness treatment.[38],[39] More recently, a study has suggested that a lower follicular enzymatic activity threshold is required for bioactivation of OM compared to topic minoxidil, suggesting that the scalp would be more susceptible to OM.[12] Based on the past literature, absorption of topical minoxidil appears to be slower and lesser when compared to OM.[ 40,41] In addition, as OM suffers liver metabolization and has a higher bioavailability compared to topical minoxidil, it is hypothesized that the oral formulation is more effective in treating hair loss in relation to topical formulation because of increased active compound in the hair follicle area. However, no previous studies had analyzed the in situ concentration of both treatment options.
Here, we identified studies evaluating the effect of OM in four different types of alopecia (alopecia areata, AGA, traction alopecia, and telogen effluvium). The doses of OM used in this review varied extremely, from 0.25 mg to 10 mg/day, in various regimens, from one to four times a day. The duration of the trials ranged from 6 to 12 months. Despite different administration regimens, studies had suggested that a minimum of 6 months is required for any cosmetic response.[14],[16] However, more randomized clinical trials, with different doses and regimens, are needed to obtain a more precise information about posology. We did not analyze any study appraising the influence of OM in scarring/cicatricial alopecias. Considering the pathogenesis of AGA, OM might be an important mediator for clinical improvement, as shorten of telogen phase and prolongation of anagen phase is a proposed mechanism of action that counteracts the observed hair growth changes occurring in this disorder. In addition, a recent study showed in a cell model experiment that minoxidil caused a significant downregulation of 5α-reductase type 2 gene expressions (−0.22 fold change), compared with untreated control cells,[42] potentially suggesting an addition mechanism of action in AGA. Similarly, taking into account the pathophysiology of alopecia areata (inflammation and hair cycle changes), OM is likely to have a direct influence in the natural course of the disorder.[43] Clearly, additional high-quality studies are needed to elucidate the mechanisms of action of OM and its impact in the pathogenesis of different types of alopecia.
Adverse effects were one of the most commonly addressed outcomes associated with OM treatment. Hypertrichosis incidence ranged from 4.0% to 93.0% and fundamentally suggests that the drug also increased the anagen interval away from the scalp. However, hypertrichosis in unwanted body's zones was not associated with a low compliance in the selected studies and was frequently resolved with simple hair removal techniques, such as laser therapy, depilatory creams, waxing, and electrolysis. In addition, peripheral edema (0.22%–10.0%) was recognized in most of studies, associated with the known vasodilator effect of minoxidil and associated sodium and fluid retention. No severe hypotension side effects were recognized, and minor complications (i.e., headaches and dizziness) resolved spontaneously. In all analyzed studies (retrieving a total of 19,270 patients), only one patient declared discontinuation of treatment because of side effects (pedal edema).[28] Furthermore, one study stated that 33 patients discontinued taking OM because of lack of efficacy or personal reasons. Alternative, but not severe, adverse effects included headaches, depression, hair shedding, electrocardiogram abnormalities (including occasional premature ventricular contractions and T-wave changes), and acne. Considering potential adverse effects related to OM, it is essential to physicians to successfully perform the shared decision model, considering the best available evidence, understanding patients' fears and expectations over the treatment, reviewing previous therapies, and assessing the benefit versus risk associated with the intervention.[44]
Interestingly, it was noted a remarkable absence or inconsistent use of standardized alopecia assessment tools (pre- and posttreatment) that are both reliable and accurate. In selected studies, the data related to alopecia were measured and reported differently; thus, we could not mathematically combine them and conduct meta-analysis due to high heterogeneity. Regarding this, we suggest an evaluation tool for dermatologist when approaching any type of alopecia whether in interventional studies or clinical trials. A high-quality global photographic assessment (before, during, and posttreatment) is fundamental, and each alopecia must be evaluated in a different pattern.[45] For instance, alopecia areata, Severity of Alopecia Tool,[46],[47] is the most suitable. For AGA, there are several scales, but the most used are Norwood–Hamilton for males and Ludwig and Olsen for females.[47] Trichoscopy (representing results as THD/cm2, DTH/cm2, NH/cm2, and NTH/cm2) using TrichoScan[48] is also a useful tool to measure the effect of a treatment in AGA.
A major strength of this systematic review is that we adhered to guidelines of the PRISMA and Cochrane Handbook for Systematic Reviews throughout the full revision process: planning the review, defining search strategies and selecting adequate studies, collecting data, assessing the risk of bias, statistically analyzing extracted data, and interpreting results analysis. Regarding this, the authors of this review made every effort to minimize bias during the review execution, independently extracting data, and assessing bias. An important limitation of the present study is the fact that only one randomized controlled trial was identified through our sensitive search strategy, evidencing a lack of literature related to OM, and its use for alopecia. Therefore, future works should focus on assessing, via high-quality randomized controlled trials, OM at different doses for appropriate and safe use of OM for the treatment of alopecia.
| Conclusion | | |
Based on this review, there is insufficient evidence to support the use of OM for alopecia in human populations. OM appears to have positive effects on improving hair regrowth in patients with different types of alopecia, but data in this review are of very low quality, suggesting that future research is extremely likely to have a fundamental impact on our confidence in the estimate of effect. Furthermore, OM is also related to various adverse events, and four out of the nine included studies were funded by pharmaceutical companies. Therefore, currently, the available evidence to support the use of OM in any type of alopecia is very low-to-low quality.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| Supplemental Material | | |
Effect of oral minoxidil for alopecia: Systematic review and meta-analysis
Important note: This form contains, essentially, all information to be analyzed and extracted in the target selected studies. Potentially, not all characteristics can be extracted in a single study. Even if only one information is obtained, please, still consider this study for the systematic review
1. General information*
2. Eligibility*
3. Outcomes measured and results identified
| References | | |
| 1. | Deborah Pergament, It's not just hair: Historical and cultural considerations for an emerging technology. Chicago Kent Law Rev 1999;75:21.  |
| 2. | Hoover E, Alhajj M, Flores JL. Physiology. Hair [Updated 2019 Aug 10]. In: StatPearls [Internet]. Treasure Island, (Florida): StatPearls Publishing; 2020 Jan. Available from: www.ncbi.nlm.nih.gov/books/NBK499948. [Last accessed on 2020 Aug 10]. |
| 3. | |
| 4. | |
| 5. | |
| 6. | Azulay RD. [Dermatology]. 7 th ed. Rio de Janeiro: Guanabara Koogan, 2017. |
| 7. | |
| 8. | |
| 9. | |
| 10. | Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006;12:53-76. |
| 11. | Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol 2018;17:457-63. |
| 12. | Ramos PM, Goren A, Sinclair R, Miot HA. Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. J Eur Acad Dermatol Venereol 2020;34:e40-1. |
| 13. | Zins GR. The history of the development of minoxidil. Clin Dermatol 1988;6:132-47. |
| 14. | Vañó-Galván S, Camacho F. New treatments for hair loss. Actas Dermosifiliogr 2017;108:221-8. |
| 15. | Sadick NS. New-Generation Therapies for the Treatment of Hair Loss in Men. Dermatol Clin 2018;36:63-7. |
| 16. | Najem I, Chen H. Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. J Cosmet Laser Ther 2018;20:252-7. |
| 17. | van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2016;2016:CD007628. |
| 18. | Freire PC, Riera R, Martimbianco AL, Petri V, Atallah AN. Minoxidil for patchy alopecia areata: Systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2019;33:1792-9. |
| 19. | Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol 2017;77:136-4100000. |
| 20. | Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097. |
| 21. | Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan – A web and mobile app for systematic reviews. Syst Rev. 2016;5:210. |
| 22. | Higgins JPT, Altam DG, Gøtzche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. |
| 23. | Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. |
| 24. | Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. |
| 25. | StataCorp, Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019. |
| 26. | Beach RA. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther 2018;31:e12707. |
| 27. | Jimenez-Cauhe J, Corralo-Saceda D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM, Fernandez-Nieto D, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol 2019;81:648-9. |
| 28. | Lueangarun S, Panchaprateep R, Tempark T, Noppakun N. Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. J Am Acad Dermatol 2015;72:AB113. |
| 29. | Ramos PM, Sinclair RD, Kasprzak M, Mio HA. Minoxidil 1 mg oral versus minoxidil 5% solution topically for the treatment of female pattern hair loss: A randomized clinical trial. J Am Acad Dermatol 2020;82:252-3. |
| 30. | Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic Alopecia Treatment in Asian Men. J Clin Aesthet Dermatol 2018;11:32-5. |
| 31. | Sinclair RD. Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol 2018;57:104-9. |
| 32. | Fiedler-Weiss VC, Rumsfield J, Buys CM, West DP, Wendrow A. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol 1987;123:1488-90. |
| 33. | Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol 2019;S0190-9622(19)32688-X. |
| 34. | Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res 2017;6:1650. |
| 35. | Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. |
| 36. | Bury M (2009). The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders - by Conrad P. Sociology of Health & Illness, 31:147-148. doi:10.1111/j.1467-9566.2008.01145_1.x. |
| 37. | Limas CJ, Freis ED. Minoxidil in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs. Am J Cardiol 1973;31:355-61. |
| 38. | Center for Drug Evaluation and Research. Pharmacology Review. U.S. Department of Health and Human Services, FDA; 2005. |
| 39. | Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol.1979;101(5):593-595. |
| 40. | Toxicology Data Network, Minoxidil, in U.S National Library of Medicine. TOXNET: United States of America; 2003. |
| 41. | Eller MG, Szpunar GJ, Della-Coletta AA. Absorption of minoxidil after topical application: Effect of frequency and site of application. Clin Pharmacol Ther 1989;45:396-402. |
| 42. | Pekmezci E, Turkoglu M. Minoxidil acts as an antiandrogen: A study of 5alpha-reductase type 2 gene expression in a human keratinocyte cell line. Acta Dermatovenerol Croat 2017;25:271-5. |
| 43. | Pratt CH, King Jr LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers 2017;3:17011. |
| 44. | Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: A model for clinical practice. J Gen Intern Med 2012;27:1361-7. |
| 45. | Gupta M, Mysore V. Classifications of patterned hair loss: A review. J Cutan Aesthet Surg 2016;9:3-12. [ PUBMED] [Full text] |
| 46. | Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol 2016;75:1268-70. |
| 47. | Olsen EA, Hordinsky M, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Der matol 2004;51:440-7. |
| 48. | Hoffmann R. TrichoScan: A novel tool for the analysis of hair growth in vivo. J Investig Dermatol Symp Proc 2003;8:109-15. |
[Figure 1], [Figure 2]
[Table 1], [Table 2]
| This article has been cited by | | 1 |
[Translated article] Morning Periorbital Edema Related to Low-Dose Oral Minoxidil |
|
| J.F. Mir-Bonafé, M. Mir-Bonafé, E. Rozas-Muñoz, J.M. Mir-Bonafé | | Actas Dermo-Sifiliográficas. 2023; | | [Pubmed] | [DOI] | | | 2 |
Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study |
|
| Belen de Nicolas-Ruanes, Oscar M. Moreno-Arrones, David Saceda-Corralo, Angela Hermosa-Gelbard, Rita Rodrigues-Barata, Rocio Gil-Redondo, Emilio Garcia-Mouronte, Sergio Vañó-Galván | | Journal of the American Academy of Dermatology. 2022; | | [Pubmed] | [DOI] | | | 3 |
Discovery of Potential Neuroprotective Agents against Paclitaxel-Induced Peripheral Neuropathy |
|
| Yi-Fan Chen, Chien-Huang Wu, Li-Hsien Chen, Hao-Wei Lee, Jinq-Chyi Lee, Teng-Kuang Yeh, Jang-Yang Chang, Ming-Chen Chou, Hui-Ling Wu, Yen-Po Lai, Jen-Shin Song, Kai-Chia Yeh, Chiung-Tong Chen, Chia-Jui Lee, Kak-Shan Shia, Meng-Ru Shen | | Journal of Medicinal Chemistry. 2022; | | [Pubmed] | [DOI] | | | 4 |
Effects of taxifolin from enzymatic hydrolysis of Rhododendron mucrotulatum on hair growth promotion |
|
| Sun-Min Park, Yi-Chang He, Chun Gong, Wei Gao, Young-Soo Bae, Chuanling Si, Kwang-Hyun Park, Sun-Eun Choi | | Frontiers in Bioengineering and Biotechnology. 2022; 10 | | [Pubmed] | [DOI] | | | 5 |
Regulation of Cytokines and Dihydrotestosterone Production in Human Hair Follicle Papilla Cells by Supercritical Extraction-Residues Extract of Ulmus davidiana |
|
| Ye-Eun Kwon, Sun-Eun Choi, Kwang-Hyun Park | | Molecules. 2022; 27(4): 1419 | | [Pubmed] | [DOI] | | | 6 |
Coupling of Fused Deposition Modeling and Inkjet Printing to Produce Drug Loaded 3D Printed Tablets |
|
| Laura Andrade Junqueira, Atabak Ghanizadeh Tabriz, Francisco José Raposo, Luana Rocha Carobini, Urias Pardócimo Vaz, Marcos Antônio Fernandes Brandão, Dennis Douroumis, Nádia Rezende Barbosa Raposo | | Pharmaceutics. 2022; 14(1): 159 | | [Pubmed] | [DOI] | | | 7 |
ALOPECIA ANDROGENÉTICA: MINOXIDIL ORAL VERSUS OUTRAS TERAPIAS MEDICAMENTOSAS |
|
| André Mendes Figueirêdo, Lívio Vasconcelos do Egypto | | Revista Contemporânea. 2022; 2(3): 385 | | [Pubmed] | [DOI] | | | 8 |
Menopause, skin and common dermatoses. Part 1: hair disorders |
|
| Erin Kamp, Mariha Ashraf, Esra Musbahi, Claudia DeGiovanni | | Clinical and Experimental Dermatology. 2022; | | [Pubmed] | [DOI] | | | 9 |
Comprehensive review of oral minoxidil in alopecia |
|
| Jay D. Modha, Yashdeep Singh Pathania | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 10 |
Edema periorbitario matutino por minoxidil oral a dosis bajas |
|
| J.F. Mir-Bonafé, M. Mir-Bonafé, E. Rozas-Muñoz, J.M. Mir-Bonafé | | Actas Dermo-Sifiliográficas. 2022; | | [Pubmed] | [DOI] | | | 11 |
Immunomorphological features of women's skin with androgenetic alopecia in the treatment of plasma enriched with platelets in combination with topical minoxidil 2 % lotion |
|
| Olena Salyenkova, Svitlana Danyliuk, Yuliya Ovcharenko | | The Journal of V. N. Karazin Kharkiv National University, Series "Medicine". 2021; (43): 83 | | [Pubmed] | [DOI] | | | 12 |
Pharmacological Management of Pattern Hair Loss |
|
| Sandeep Suresh Sattur, Indu Sandeep Sattur | | Indian Journal of Plastic Surgery. 2021; | | [Pubmed] | [DOI] | |
|
 |
|
|
|
